First clinically-focused systematic review found CBD promising for social anxiety and possibly schizophrenia, but evidence is embryonic
The first clinically-focused systematic review of cannabis for psychiatric disorders found tentative support for CBD in social anxiety and mixed positive evidence for adjunctive CBD in schizophrenia, with high-THC formulations showing no benefit for depression.
Quick Facts
What This Study Found
CBD showed tentative support for reducing social anxiety. Mixed but mainly positive evidence supported adjunctive CBD in schizophrenia. Case studies suggested benefits for sleep and PTSD. High-THC therapeutics showed no benefit for depression. One study suggested oral cannabinoid/terpene combinations may help ADHD. Key prescriptive caution: avoid high-THC in youth, anxiety-prone, or psychosis-prone individuals; titrate gradually; monitor cardiovascular and respiratory function.
Key Numbers
CBD: tentative support for social anxiety; mixed positive for schizophrenia adjunct; case-study level for sleep and PTSD; high-THC: no depression benefit; one study suggests cannabinoid/terpene for ADHD.
How They Did This
Systematic review of all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for major psychiatric disorders (2019), including clinical prescription considerations and pharmacogenomics.
Why This Research Matters
This is described as the first clinically-focused systematic review covering all major psychiatric disorders. It bridges the gap between research evidence and clinical practice, providing specific prescribing guidance alongside the evidence.
The Bigger Picture
The pattern is clear: CBD shows promise while high-THC formulations show risk. This has direct implications for how medicinal cannabis should be prescribed for psychiatric conditions: CBD-dominant formulations with careful THC avoidance in vulnerable populations.
What This Study Doesn't Tell Us
Evidence described as "embryonic" by authors; most psychiatric disorder evidence at case-study level; systematic review encompasses heterogeneous study types; pharmaceutical CBD and whole-plant products may differ; limited long-term safety data.
Questions This Raises
- ?Is CBD alone sufficient for psychiatric benefits, or do trace cannabinoids contribute?
- ?What dose and duration of CBD are optimal for social anxiety?
Trust & Context
- Key Stat:
- CBD: promising for social anxiety; high-THC: no benefit for depression
- Evidence Grade:
- Moderate: comprehensive systematic review with clinical focus, but underlying evidence is mostly embryonic.
- Study Age:
- Published 2020.
- Original Title:
- Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
- Published In:
- BMC psychiatry, 20(1), 24 (2020)
- Authors:
- Sarris, Jerome(9), Sinclair, Justin(14), Karamacoska, Diana, Davidson, Maggie, Firth, Joseph
- Database ID:
- RTHC-02821
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can medical cannabis treat psychiatric disorders?
This review found tentative support for CBD in social anxiety and mixed positive evidence for CBD as an add-on in schizophrenia. Case studies suggest benefits for sleep and PTSD. However, high-THC products showed no benefit for depression and carry risks for anxiety and psychosis-prone individuals.
Should I use CBD or THC for mental health?
Based on this review, CBD appears more promising and safer for psychiatric conditions. High-THC formulations should be avoided in youth, people with anxiety disorders, and those at risk for psychosis. The authors emphasize gradual titration and regular monitoring.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02821APA
Sarris, Jerome; Sinclair, Justin; Karamacoska, Diana; Davidson, Maggie; Firth, Joseph. (2020). Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.. BMC psychiatry, 20(1), 24. https://doi.org/10.1186/s12888-019-2409-8
MLA
Sarris, Jerome, et al. "Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.." BMC psychiatry, 2020. https://doi.org/10.1186/s12888-019-2409-8
RethinkTHC
RethinkTHC Research Database. "Medicinal cannabis for psychiatric disorders: a clinically-f..." RTHC-02821. Retrieved from https://rethinkthc.com/research/sarris-2020-medicinal-cannabis-for-psychiatric
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.